Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Neoadjuvant and Adjuvant in Resectable NSCLC (LCMC3)
NCT02927301Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Primary endpoint: Percentage of Participants With Major Pathologic Response at 10 weeks. Started Apr 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02927301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927301.